Envoy Medical to Participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) Conference on October 11th-14th
White Bear Lake, Minnesota--(Newsfile Corp. - October 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that management will participate in the American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) conference taking place on October 11th-14th, 2025 in Indianapolis, IN, at the Indiana Convention Center and JW Marriott Indianapolis
Biotechnology, Healthcare and Hospitals
2025-10-01 8:00 AM EDT | Envoy Medical, Inc.
Former Canadian Coatings Association President & CEO Gary LeRoux joins Biosenta's Advisory Board
Ontario and Calgary, Alberta--(Newsfile Corp. - October 1, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") today announced that Gary LeRoux, past President and CEO of the Canadian Coatings Association (CCA), has joined the company's advisory board.
Biotechnology, Chemical, Household / Consumer / Cosmetics
2025-10-01 8:00 AM EDT | Biosenta Inc.
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it has entered into a definitive Asset Purchase Agreement (the "Agreement") for the sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a well-established global pharmaceutical co
Biotechnology, Pharmaceuticals
2025-10-01 8:00 AM EDT | PharmaTher Holdings Ltd.
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that it has signed debt-to-equity conversion agreements with vendors to convert approximately CAD $13.3 million of outstanding accounts payable debt into equity of Sernova. T
2025-10-01 7:00 AM EDT | Sernova Biotherapeutics
Scryb Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") announces that it has granted 3,870,000 stock options (the "Options") to various employees, directors, officers and consultants of the Company. Each Option is exercisable at a price of $0.12 for one common share of the Company (each a "Common Share") for a period of five years from the da
Biotechnology, Healthcare and Hospitals, Health
2025-09-30 8:04 PM EDT | Scryb Inc.
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update
Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announces the relocation and expansion of its clinical laboratories and offices from the MaRS startup incubation hub into a new, state-of-the-art clinical laboratory space in the Greater Toronto Area. The relocati
2025-09-30 4:30 PM EDT | Telo Genomics Corp.
OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update
Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting feedback from UK MHRA In principle, UK MHRA accepts use of historical control arm to support conditional MAA UK MHRA conditional MAA and US FDA Biologics Licensing Application (BLA) submissions expected to be completed wit
2025-09-30 7:40 AM EDT | OS Therapies
BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce the formal grant of patents in both China and Japan. These new patents cover its innovative metabolic liquid biopsy platform for the rapid, non-invasive detection of lung cancer. The newly granted Chinese patent (N° ZL 201980092723.X) a
Technology, Biotechnology, Healthcare and Hospitals
2025-09-29 8:30 AM EDT | BioMark Diagnostics, Inc.
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas healthcare is experiencing a historic breakthrough with the approval of House Bill 46 (HB 46). Signed into law on June 21, 2025, by Governor Greg Abbott, the expansion of the Texas Compassionate Use Program (TCUP) will cover chronic pain, PTSD, and degenerative neurological conditions, among othe
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-09-29 7:00 AM EDT | Cannabis Bioscience International Holdings
Quantum BioPharma Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-26 8:00 PM EDT | Quantum BioPharma Ltd.
Scryb Closes Oversubscribed Private Placement for over $1.4M
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company"), is pleased to announce it has completed its previously announced upsized non-brokered private placement offering, issuing 14,709,700 units of the Company (each, a "Unit"), at a price of $0.10 per Unit, for gross proceeds of $1,470,970 (the "Offering"). The original offering was announced for up to 6,000,000 Units of the Company on September 17, 2025, and
Biotechnology, Healthcare and Hospitals, Health
2025-09-26 7:03 PM EDT | Scryb Inc.
Oliver Technow Receives the 2025 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Oliver Technow, former Chief Executive Officer of BIOVECTRA, as the recipient of the 2025 Bloom Burton Award.
Technology, Biotechnology, Investment Banking, Health
2025-09-26 7:36 AM EDT | Bloom Burton & Co. Inc.
MustGrow Announces Grant of RSUs and DSUs
Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors of the Company authorized and approved the grant of a total of 1,660,315 deferred share units ("DSUs") and restricted share units ("RSUs") to certain directors, officers, and consultants of the Company, effective September 25, 2025. This grants of DSUs and
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-09-26 7:00 AM EDT | MustGrow Biologics Corp.
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors. Detailed voting results for the ele
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-25 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Envoy Medical Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - September 25, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock. In addition, in a concurrent private plac
Biotechnology, Healthcare and Hospitals
2025-09-25 8:00 AM EDT | Envoy Medical, Inc.
Envoy Medical Advances Commercialization Planning for Breakthrough Hearing Device as FDA Clinical Trial Remains On Track
White Bear Lake, Minnesota--(Newsfile Corp. - September 24, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing
Biotechnology, Healthcare and Hospitals
2025-09-24 8:00 AM EDT | Envoy Medical, Inc.
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral cand
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-09-24 7:00 AM EDT | Theralase Technologies Inc.
Kneat Recognised as Leader in G2 Pharma and Biotech Fall 2025 Grid Reports
Limerick, Ireland--(Newsfile Corp. - September 24, 2025) - kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, has been awarded the top position in three of G2 Software Review's Fall 2025 Pharma and Biotech Software category reports. Kneat was recognized as: Leader in the Grid® Report for Pharma and Biotech
2025-09-24 6:37 AM EDT | kneat.com, inc
Therma Bright Expands Relationship with Distribution Partner Gen-X Med for Venowave(TM) Sales
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce a strategic partnership with Gen-X Med, a specialized medical product distributor based in Arlington, Texas. The partnership was hatched after the initial sale of 200 Venowave™ VW5 units that targeted patients th
Technology, Biotechnology, Health
2025-09-24 6:30 AM EDT | Therma Bright Inc.
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to ann
Biotechnology, Pharmaceuticals, Health
2025-09-23 12:22 PM EDT | Hemostemix Inc.